Helping restore sex drive during hormone therapy for breast cancer
Treatments studied
Part of Cancer, Mental health, Skin clinical trials.
This trial tests a medication called bupropion to see if it can help increase sex drive in women who have a reduced interest in sex due to hormone-blocking therapy for breast cancer. The goal is to make it easier for women to stick with their hormone treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with early-stage (stage I, II, or III) hormone receptor-positive breast cancer, meaning your cancer cells have receptors for hormones like estrogen or progesterone.
- You have completed your scheduled treatments for breast cancer, including surgery, radiation (if needed), and chemotherapy (if needed).
- You are able to swallow pills and are willing to fill out questionnaires and return for follow-up visits.
- You are not taking certain psychiatric medications (like antidepressants) and do not have a history of seizures, high blood pressure, or certain eye conditions.
- If you are of childbearing age, you must agree to use effective contraception and must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This trial tests a new approach to reduce hot flashes in women taking hormone therapy for breast cancer. You may be able to join if you have at least 14 hot flashes a week and are not taking certain other treatments.
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
Hear when a new Early-stage Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.